CRVS
Corvus Pharmaceuticals Inc
NASDAQ: CRVS · HEALTHCARE · BIOTECHNOLOGY
$15.19
+5.34% today
Updated 2026-04-30
Market cap
$1.35B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.53
Dividend yield
—
52W range
$3 – $27
Volume
1.3M
Corvus Pharmaceuticals Inc (CRVS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-104727.00 | $-11.33M | $-27.86M | $-46.21M | $-40.99M | $-37.32M | $-34.78M | $-36.72M | $-27.02M | $-23.93M | $-25.42M | $-32.80M |
| Capital expenditures | $1.75M | $1.75M | $2.20M | $266000.00 | $355000.00 | $25000.00 | $76000.00 | $5000.00 | $269000.00 | $34000.00 | $0.00 | $174000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $428000.00 | $3.83M | $6.23M | $7.13M | $7.35M | $5.75M | $4.23M | $2.69M | $2.15M | $3.00M | $5.33M |
| Free cash flow | $-1.85M | $-13.07M | $-30.06M | $-46.48M | $-41.34M | $-37.35M | $-34.85M | $-36.72M | $-27.29M | $-23.97M | $-25.42M | $-32.97M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $945000.00 | $40.06M | $-5.91M | $-34.04M | $11.30M | — | — | — | — | — |